Novartis' del-desiran misses Phase III primary endpoint in myotonic dystrophy type 1
What's the deal? On 8 September 2026, Novartis announced that its Phase III HARBOR study of delpacibart etedesiran (del-desiran) in myotonic dystrophy type 1 (DM1) did not meet its primary endpoint — video hand opening time (vHOT), a novel measure of hand myotonia — versus placebo. The Avidity Biosciences-originated antibody–oligonucleotide conjugate (AOC) did show evidence of clinical activity on secondary endpoints and exploratory analyses, with safety consistent with prior data. Novartis is evaluating the full dataset and will engage with health authorities on the most appropriate path forward.
Why it matters: DM1 is a progressive neuromuscular disease with no approved treatment options — "patients and caregivers continue to face a significant daily burden," said Shreeram Aradhye, President, Development and Chief Medical Officer, who framed the miss as "part of scientific progress." The AOC pipeline Novartis gained through the Avidity acquisition keeps advancing: the FDA has granted priority review to delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy patients amenable to exon 44 skipping (DMD44), and Novartis plans an FDA meeting for delpacibart braxlosiran (del-brax) in FSHD on the back of positive Phase I/II biomarker data. Novartis maintained its 5–6% five-year sales CAGR guidance for 2025–2030.
Read more: Novartis media release, 8 September 2026